Home Blog
A few rotten apples may indeed spoil the whole bunch—if the bunch happens to be an organoid, a cluster of cells grown in the laboratory to mimic an organ. Kidney organoids, for example, are used to study how real kidneys work and respond to newly developed treatments. But if kidney organoids contain wayward non-kidney cells, they may fail to...
Improving how chemotherapy is delivered to cancer cells is a major concern for researchers and drug manufacturers. One of the big issues with chemotherapy is that most treatment approaches focus on the tumor itself without paying significant attention to the microenvironment surrounding the tumor. Now, investigators at Purdue University have developed new technology aimed at making it easier to...
Brain Gut
Scientists report that brown fat interacts with the gut hormone secretin in mice to relay nutritional signals about fullness to the brain during a meal. Study reinforces our understanding of a long-suspected role of brown adipose tissue, a type of body fat known to generate heat when an animal is cold, in the control of food intake.
Scanning electron microscope of breast cancer cell
A drug previously approved for treating migraine and epilepsy has been found to slow the growth of triple negative breast cancer in mouse models. Researchers carried out screening studies to identify known pharmacologically active compounds that trigger degradation of N-Ras, a key protein that drives the development of aggressive basal-like breast cancer.
AstraZeneca and its MedImmune subsidiary acknowledged today that their marketed anticancer treatment Imfinzi™ (durvalumab) failed the second of two primary endpoints in a Phase III trial designed to assess the programmed death-ligand 1 (PD-L1) blocking antibody alone and in combination with the companies’ anti-CTLA4 antibody tremelimumab in a form of non-small cell lung cancer (NSCLC). The Imfinzi-tremelimumab combination missed the second...
GE_Custom made, autologous cell therapies
The success of cell therapies hinges on not only proving that a product elicits the desired biological response, but also overcoming the challenges of manufacturing and administering a complex product to any patient.
Named after the two-faced god, newly developed Janus nucleic acid recognition elements target double-stranded DNA or RNA by engaging both strands at once. When strung together within a single-stranded protein nucleic acid (PNA), a synthetic construct, Janus elements may bind to natural targets in a sequence-specific manner. What’s more, Janus elements, like Janus himself, looks backwards and forwards at...
Homecare nurse helping elderly lady to take her daily medicine.
Scientists at the Salk Institute have identified a new subclass of anti-aging geroprotector compounds that can slow aging in mice and could represent promising drug candidates for Alzheimer's disease (AD). Early studies in different rodent models suggest that the compounds, termed geroneuroprotectors (GNPs), improve memory and reduce hallmark toxicities associated with AD. Preclinical studies are ongoing with a view...
Mallotus
Traditional herbal medicines used for centuries often have tangible physiologic and therapeutic value. Yet, for these remedies to be successful for the masses the underlying cellular and molecular properties need to be carefully teased out and assessed for safety and effectiveness. In that vein, investigators in the department of physiology & biophysics at the University of California, Irvine School...
United Therapeutics has acquired exclusive global rights to Arena Pharmaceuticals’ Phase III pulmonary arterial hypertension (PAH) candidate ralinepag (APD811), in a licensing deal that could generate more than $1.2 billion for Arena, the companies said today. Ralinepag (APD811) is a next-generation, oral, selective potent, once-daily prostacyclin receptor (IP) agonist intended for PAH. According to Arena, ralinepag's application as a potentially...

Recently Featured

Stay Connected

558,415FansLike
45,340FollowersFollow
Scroll Up